-transparent.png){kind=logo}
Serum glycoprotein hormone alpha-subunit levels were determined in 165 patients with pituitary adenomas. Elevated serum alpha-subunit levels were found in 17 patients (acromegaly, 5 of 58; prolactinoma, 6 of 56; nonfunctioning adenoma, 5 of 32; and ACTH-producing adenoma, 1 of 19), most of whom had normal serum TSH and gonadotropin levels. When TRH (0.5 mg) was injected iv in the 6 prolactinoma patients with elevated serum alpha-subunit levels, serum PRL and alpha-subunit levels increased in only 1 patient. Four acromegalic patients with high serum alpha-subunit levels received TRH; serum GH and alpha-subunit increased in 1 patient and did not change in 2, and only serum GH increased in the remaining patient. Oral administration of bromocriptine (5 mg), on the other hand, consistently decreased serum alpha-subunit and PRL levels in 2 patients with prolactinoma and alpha-subunit and GH levels in 1 acromegalic patient. When serum from 3 patients was subjected to Sephadex G-100 gel filtration, immunoreactive alpha-subunit eluted in a single peak, which emerged in fractions corresponding to [125I]TSH alpha. Concanavalin A (Con A) affinity chromatography revealed that the major portion of immunoreactive alpha-subunit was retained to Con A. A pituitary adenoma removed at surgery from a patient with acromegaly was studied in monolayer cell culture. Secretion of both alpha-subunit and GH from cultured adenoma cells was stimulated by TRH and suppressed by dopamine in a dose-dependent manner. Immunohistochemistry of the pituitary adenomas removed from patients with prolactinoma and acromegaly who had high serum alpha-subunit levels demonstrated alpha-subunit-containing cells as well as PRL- or GH-containing cells. These results suggest that elaboration of glycoprotein hormone alpha-subunit occurs without concurrent production of glycoprotein hormones in a substantial number of patients with pituitary adenomas and that alpha-subunit responses to stimuli in such adenomas are generally parallel with those of the concomitantly produced hormones.
M Ishibashi, and
T Yamaji, and
F Takaku, and
A Teramoto, and
T Fukushima
July 2010,
Nihon rinsho. Japanese journal of clinical medicine,
M Ishibashi, and
T Yamaji, and
F Takaku, and
A Teramoto, and
T Fukushima
August 2005,
Nihon rinsho. Japanese journal of clinical medicine,
M Ishibashi, and
T Yamaji, and
F Takaku, and
A Teramoto, and
T Fukushima
September 1980,
Clinical endocrinology,
M Ishibashi, and
T Yamaji, and
F Takaku, and
A Teramoto, and
T Fukushima
October 1997,
Orvosi hetilap,
M Ishibashi, and
T Yamaji, and
F Takaku, and
A Teramoto, and
T Fukushima
January 1999,
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
M Ishibashi, and
T Yamaji, and
F Takaku, and
A Teramoto, and
T Fukushima
July 1976,
The Journal of clinical endocrinology and metabolism,
M Ishibashi, and
T Yamaji, and
F Takaku, and
A Teramoto, and
T Fukushima
March 1992,
Trends in endocrinology and metabolism: TEM,
M Ishibashi, and
T Yamaji, and
F Takaku, and
A Teramoto, and
T Fukushima
February 1994,
Endocrinology,
M Ishibashi, and
T Yamaji, and
F Takaku, and
A Teramoto, and
T Fukushima
December 1991,
The Journal of clinical endocrinology and metabolism,
M Ishibashi, and
T Yamaji, and
F Takaku, and
A Teramoto, and
T Fukushima
January 1989,
Polski tygodnik lekarski (Warsaw, Poland : 1960),
